A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-nave Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
- Sponsor:
- Merck
- Sponsor Study ID:
- MK2140-011
- CTO #:
- 104156
- NCT Number:
- NCT06890884
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Non-Hodgkin's Lymphoma
- Study Objectives:
- To compare zilovertamab vedotin plus R-CHP with polatuzumab vedotin plus R-CHP with respect to CR rate at EOT per Lugano response criteria as assessed by BICR.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Antel, Katherine, at antelk@musc.edu .
- Study Coordinator, Mendiola, Hannah, at mendiola@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina